IMTX Key Statistics, Chart & Performance
The current stock price of IMTX is 9.17 USD. In the past month the price decreased by -8.85%. In the past year, price increased by 42.61%.
IMTX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.29 | 388.96B | ||
| AMGN | AMGEN INC | 14.91 | 175.60B | ||
| GILD | GILEAD SCIENCES INC | 14.79 | 150.25B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.72 | 117.69B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.7 | 83.72B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 780.96 | 52.62B | ||
| INSM | INSMED INC | N/A | 37.53B | ||
| NTRA | NATERA INC | N/A | 32.34B | ||
| BIIB | BIOGEN INC | 11.21 | 27.52B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 22.94B | ||
| INCY | INCYTE CORP | 16.65 | 20.98B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.31 | 20.81B |
Related stock screener links
About IMTX
Company Profile
Immatics NV is a clinical stage biopharmaceutical company, which engages in the research and development of T cell receptor-based immunotherapies for the treatment of cancer. The company is headquartered in Tuebingen, Baden-Wuerttemberg and currently employs 297 full-time employees. The company went IPO on 2020-07-02. The firm is focused on the discovery and development of T-Cell eceptors with the goal of enabling a robust and specific T-Cell response against these targets. The firm develops targeted immunotherapies with an emphasis on treating solid tumors through two distinct therapeutic modalities: Adoptive Cell Therapies (ACT) and antibody-like TCR Bispecifics (TCER). Its wholly owned pipeline comprises of eight therapeutic programs, of which four are in clinical trials, including IMA201 (MAGEA4/8), IMA202 (MAGEA1) and ACTolog IMA 101 (Multi-target pilot trial) for solid cancers and IMA203 (PRAME) for hematological and solid cancers, as well as four are in preclinical development, including IMA204 (COL6A3) and IMA401 (Cancer testis antigen) for solid cancers, and ACTallo IMA301 (Cancer testis antigen) and IMA402 (Cancer testis antigen) for hematological and solid cancers.
Company Info
IMMATICS NV
Paul Ehrlich-Strasse 15
Tuebingen BADEN-WUERTTEMBERG 72076 DE
CEO: Harpreet Singh
Employees: 297
Phone: 4970715397700
IMMATICS NV / IMTX FAQ
What does IMTX do?
Immatics NV is a clinical stage biopharmaceutical company, which engages in the research and development of T cell receptor-based immunotherapies for the treatment of cancer. The company is headquartered in Tuebingen, Baden-Wuerttemberg and currently employs 297 full-time employees. The company went IPO on 2020-07-02. The firm is focused on the discovery and development of T-Cell eceptors with the goal of enabling a robust and specific T-Cell response against these targets. The firm develops targeted immunotherapies with an emphasis on treating solid tumors through two distinct therapeutic modalities: Adoptive Cell Therapies (ACT) and antibody-like TCR Bispecifics (TCER). Its wholly owned pipeline comprises of eight therapeutic programs, of which four are in clinical trials, including IMA201 (MAGEA4/8), IMA202 (MAGEA1) and ACTolog IMA 101 (Multi-target pilot trial) for solid cancers and IMA203 (PRAME) for hematological and solid cancers, as well as four are in preclinical development, including IMA204 (COL6A3) and IMA401 (Cancer testis antigen) for solid cancers, and ACTallo IMA301 (Cancer testis antigen) and IMA402 (Cancer testis antigen) for hematological and solid cancers.
Can you provide the latest stock price for IMMATICS NV?
The current stock price of IMTX is 9.17 USD. The price decreased by -1.61% in the last trading session.
Does IMTX stock pay dividends?
IMTX does not pay a dividend.
How is the ChartMill rating for IMMATICS NV?
IMTX has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How many employees does IMMATICS NV have?
IMMATICS NV (IMTX) currently has 297 employees.
What is the market capitalization of IMTX stock?
IMMATICS NV (IMTX) has a market capitalization of 1.11B USD. This makes IMTX a Small Cap stock.
IMTX Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to IMTX. When comparing the yearly performance of all stocks, IMTX is one of the better performing stocks in the market, outperforming 73.46% of all stocks.
IMTX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to IMTX. IMTX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
IMTX Financial Highlights
Over the last trailing twelve months IMTX reported a non-GAAP Earnings per Share(EPS) of -1.05. The EPS decreased by -55.17% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -22.35% | ||
| ROE | -27.81% | ||
| Debt/Equity | 0.03 |
IMTX Forecast & Estimates
17 analysts have analysed IMTX and the average price target is 18.87 USD. This implies a price increase of 105.78% is expected in the next year compared to the current price of 9.17.
For the next year, analysts expect an EPS growth of -1210.1% and a revenue growth -66.71% for IMTX